Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 7/20 | 0.38 |
| ▸ | TDO2 | P48775 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28819817 | 0.80 | SLC6A4 (0.40) | SLC6A4ALDH1A1 | |
| SCHEMBL13232182 | 0.79 | EPHX1 (0.49) | CYP1A2CYP2D6HIF1AIDO1TDO2 | |
| SCHEMBL10021113 | 0.79 | METAP2 (0.47) | CYP1A2CYP2D6HIF1AIDO1TDO2 | |
| SCHEMBL2646161 | 0.78 | AKR1C3 (0.40) | SLC6A4ALDH1A1 | |
| SCHEMBL12742235 | 0.78 | GCK (0.38) | SLC6A4ALDH1A1 | |
| SCHEMBL1107404 | 0.78 | AKR1C3 (0.40) | SLC6A4ALDH1A1 | |
| SCHEMBL7496186 | 0.77 | CYP1A2 (0.59) | CYP1A2CYP2D6HIF1A | |
| SCHEMBL28819819 | 0.76 | ALDH1A1 (0.37) | SLC6A4ALDH1A1 | |
| SCHEMBL18660426 | 0.76 | NFE2L2 (0.44) | CYP1A2CYP2D6HIF1AIDO1TDO2 | |
| SCHEMBL10633563 | 0.76 | SLC6A2 (0.54) | SLC6A4IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102686587-B | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | disclosed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CYP1A2 580/4885CYP2D6 458/4885HIF1A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.